Veracity Capital LLC Acquires 25,030 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Veracity Capital LLC lifted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 117.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 46,415 shares of the biotechnology company’s stock after purchasing an additional 25,030 shares during the quarter. Veracity Capital LLC’s holdings in ADMA Biologics were worth $796,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hollencrest Capital Management acquired a new position in ADMA Biologics during the third quarter worth $30,000. Larson Financial Group LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth about $31,000. GAMMA Investing LLC increased its holdings in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 967 shares during the last quarter. National Bank of Canada FI bought a new position in shares of ADMA Biologics in the 3rd quarter valued at approximately $35,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in ADMA Biologics in the 3rd quarter worth approximately $62,000. Institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ADMA. HC Wainwright increased their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James raised their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th.

Insider Transactions at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Performance

ADMA opened at $16.58 on Friday. ADMA Biologics, Inc. has a 12-month low of $5.02 and a 12-month high of $23.64. The firm has a market capitalization of $3.92 billion, a P/E ratio of 59.21 and a beta of 0.76. The stock’s 50 day moving average price is $18.69 and its two-hundred day moving average price is $17.40. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter last year, the company posted $0.01 earnings per share. On average, equities analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.